Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Long-Term Prospective Quality-of-Life Outcomes in 445 Patients with Sporadic Vestibular Schwannoma
Carlson, Matthew L. , Babajanian, Eric E. , Lohse, Christine M. , Tombers, Nicole M. , Link, Michael J.

Mayo Clinic

Otology & Neurotology | October 23, 2024 | Volume: 45 | Issue: 10 | Pages: 1167-1171

10.1097/mao.0000000000004328 | PMID 39439048 Get It

Objective To evaluate the long-term changes in sporadic vestibular schwannoma (VS) disease-specific quality-of-life (QOL) outcomes. Study Design Prospective longitudinal study using the Penn Acoustic Neuroma Quality of Life (PANQOL) Scale. Setting National survey. Patients Patients with sporadic VS who completed a baseline survey before treatment and at least one follow-up survey recruited through the authors’ center and through the Acoustic Neuroma Association. Interventions Observation, microsurgery, radiosurgery. Main Outcome Measures Changes in PANQOL scores from baseline to most recent survey. Results Among 445 eligible patients the mean duration of follow-up was 4.4 (SD, 2.3) years, including 122, 218, and 105 in the observation, microsurgery, and radiosurgery groups, respectively. Patients managed with observation (p = 0.03) or microsurgery (p < 0.001) demonstrated improvement in anxiety scores. Changes in facial function scores differed significantly by management group (p = 0.01), with patients undergoing microsurgery demonstrating a mean decline of 10 points in facial function scores compared with mean declines of 3 for those managed with observation or radiosurgery. Hearing loss scores decreased similarly over time for all three groups (p = 0.3). There were minimal changes in total PANQOL scores over time across all management groups (p = 0.5). Conclusions Long-term changes in total QOL among VS management groups are not significantly different. Microsurgery may continue to confer an advantage regarding improvement in anxiety postoperatively, but with a greater decline in facial function when compared to observation or radiosurgery. Long-term declines in hearing loss scores were not statistically significantly different among groups.
A rare case of curative colectomy for Takayasu's arteritis
Kek, Laura , Reed, Griffin , Reed, Griffin J , Koster, Matthew J.

Mayo Clinic

Clinical and Experimental Rheumatology | October 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/a1okxy | PMID 39436714 Get It

Evaluation of Blood–Brain Barrier Disruption Using Low- and High-Molecular-Weight Complexes in a Single Brain Sample in a Rat Traumatic Brain Injury Model: Comparison to an Established Magnetic Resonance Imaging Technique
Zvenigorodsky, Vladislav , Gruenbaum, Benjamin F. , Shelef, Ilan , Horev, Anat , Azab, Abed N., Abu-Rabia, Mammduch, Negev, Shahar, Melamed, Israel , Boyko, Matthew , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Shelef, Ilan , Oleshko, Anna, Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | October 21, 2024 | Volume: 25 | Issue: 20 | Pages: 11241

10.3390/ijms252011241 | PMID 39457023 Get It

Traumatic brain injury (TBI), a major cause of death and disability among young people, leads to significant public health and economic challenges. Despite its frequency, treatment options remain largely unsuitable. However, examination of the blood–brain barrier (BBB) can assist with understanding the mechanisms and dynamics of brain dysfunction, which affects TBI sufferers secondarily to the injury. Here, we present a rat model of TBI focused on two standard BBB assessment markers, high- and low-molecular-weight complexes, in order to understand BBB disruption. In addition, we tested a new technique to evaluate BBB disruption on a single brain set, comparing the new technique with neuroimaging. A total of 100 Sprague–Dawley rats were separated into the following five groups: naive rats (n = 20 rats), control rats with administration (n = 20 rats), and TBI rats (n = 60 rats). Rats were assessed at different time points after the injury to measure BBB disruption using low- and high-molecular-weight complexes. Neurological severity score was evaluated at baseline and at 24 h following TBI. During the neurological exam after TBI, the rats were scanned with magnetic resonance imaging and euthanized for assessment of the BBB permeability. We found that the two markers displayed different examples of BBB disruption in the same set of brain tissues over the period of a week. Our innovative protocol for assessing BBB permeability using high- and low-molecular-weight complexes markers in a single brain set showed appropriate results. Additionally, we determined the lower limit of sensitivity, therefore demonstrating the accuracy of this method.
Rates and predictors of loss to follow-up for sporadic vestibular schwannomas undergoing imaging surveillance
Alexander, Marcus, Sáez-Alegre, Miguel , Celda, María Peris, Neff, Brian A., Carlson, Matthew L. , Driscoll, Colin L. W., Link, Michael J. , Peris Celda, Maria, Driscoll, Colin L., Morshed, Ramin A. , Bauman, Megan M. J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | October 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2024.6.jns232904 | PMID 39423436 Get It

OBJECTIVE Imaging surveillance with serial MRI, or a "wait-and-scan" approach, is a management option for patients with small or medium-sized vestibular schwannomas (VSs). Prior publications have indicated no distinct quality of life advantage to upfront treatment compared with initial wait-and-scan management. However, imaging surveillance is dependent on patient adherence to follow-up. In this study, the authors aimed to identify rates and predictors of patient loss to follow-up during wait-and-scan management of sporadic VS. METHODS A single-center study was conducted including all patients from 2013 to 2018 who had undergone upfront imaging surveillance of sporadic VS. Patient data were retrospectively obtained from the electronic medical record. Outcomes of interest included loss to follow-up unrelated to death and inconsistent adherence to imaging surveillance recommendations. Logistic regression analyses were conducted to evaluate factors associated with loss to follow-up. RESULTS Over a 6-year study period, 270 patients underwent initial imaging surveillance of a sporadic VS. The median tumor diameter was 8.6 mm (range 1–28.9 mm). At the time of censoring, 106 patients (39.3%) had received treatment, 157 (58.1%) had been advised to continue follow-up, and 7 (2.6%) had died of non–VS-related causes. In total, 73 patients (27.0%) were completely lost to follow-up prior to the first treatment or death. Additionally, 60 patients (22.2%) missed at least 1 MRI follow-up or imaging follow-up was delayed by more than 1 year. Multivariable logistic regression identified an out-of-state residence (OR 3.05, 95% CI 1.58–5.89, p = 0.0009) and a smaller tumor size (unit OR per 1-mm increase in size, OR 0.88, 95% CI 0.83–0.95, p = 0.0006) to be associated with loss to follow-up. Patients living ≥ 350 miles from the hospital or with tumors ≤ 3 mm at the time of initial clinic evaluation were most likely to be lost to follow-up. Only a smaller tumor size was associated with an increased risk of inconsistent imaging follow-up (unit OR per 1-mm increase in size, OR 0.92, 95% CI 0.87–0.98, p = 0.007). CONCLUSIONS Patients undergoing imaging surveillance of VS are at risk for loss to follow-up and inconsistent imaging surveillance. Patients with smaller tumors or those living farther away from the treating institution are at highest risk for being lost to follow-up.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Aldoss, Ibrahim , Kopmar, Noam E. , Lin, Chenyu , Dekker, Simone E. , Gupta, Vishal, O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Kate , Ahmed, Mohamed , Schwartz, Marc S. , Tracy, Sean , Mukherjee, Akash , Ladha, Abdullah , Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Pullarkat, Vinod , Muffly, Lori , Oliai, Caspian , Yaghmour, George , Sutherland, Katherine, Zambrano, Héctor, Bradshaw, Danielle , Kubiak, Michal , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Stefan, Maryann, O'Dwyer, Kristen M., Blunk, Betsy, Bishop, Michael R. , Aldoss, Ibrahim , Kopmar, Noam E , Lin, Chenyu , Gupta, Vishal K , Muhsen, Ibrahim N , Valtis, Yannis , Miller, Katharine , Chen, Evan , Mercadal, Santiago , Tracy, Sean I , Dholaria, Bhagirathbhai R , Battiwalla, Minoo , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Solh, Melham M , Kota, Vamsi , Frey, Noelle V , Park, Jae H , Luskin, Marlise R , Stock, Wendy , Cassaday, Ryan D , Muffly, Lori , Bachanova, Veronika , Roloff, Gregory W. , Ahmed, Naveed, Dykes, Kaitlyn C. , Schwartz, Marc, Dholaria, Bhagirathbhai , Battiwalla, Minoo , Hilal, Talal , Tsai, Stephanie B., Kota, Vamsi , Leonard, Jessica T , Frey, Noelle V. , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal , Faramand, Rawan , Oliai, Caspian H , Majhail, Navneet S. , Mathews, John Abraham , Advani, Anjali S. , O'Dwyer, Kristin , Lee, Catherine J , Bishop, Michael Russell

Mayo Clinic

Journal of Clinical Oncology | October 17, 2024 | Volume: 43 | Issue: 5 | Pages: 558-566

10.1200/jco.24.00321 | PMID 39418622 Get It

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.
Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma
Gile, Jennifer , Maurer, Matthew J. , Ruan, Gordon , Abeykoon, Jithma P. , Heimgartner, Joy , Baumann, N, McMahon, Molly, Gile, Jennifer Jane , Maurer, Matthew , Ruan, Gordon J , Heimgartner, Joy R, Baumann, Nikola A, Lin, Yi , Witzig, Thomas E.

Mayo Clinic

The Oncologist | October 17, 2024 | Volume: 29 | Issue: 12 | Pages: e1779-e1782

10.1093/oncolo/oyae255 | PMID 39418117 Get It

Abstract Magnesium (Mg) is an essential element involved in cellular metabolism. We demonstrated that in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (SCT), those with a serum Mg &lt; 2.0 mg/dL at the time of transplant had worse outcomes. In this study, we aimed to learn the prognostic value of low serum Mg in patients with untreated DLBCL. We analyzed serum from 408 patients and tested 2 Mg cutpoints—low (&lt;1.7 mg/dL) and low normal (&lt;2.0 mg/dL), a range we found associated with lower survival in the SCT group. We found 3% of patients with low levels and 23% with low normal levels. Low normal serum Mg levels were associated with a higher stage at diagnosis, more extranodal involvement, higher international prognostic index score, lower overall survival (OS), and event-free survival. These data warrant testing Mg replacement to a target of &gt;2.0 mg/dL to learn if survival can be improved.
Feasibility of thin-slice, low noise images created using multi-kernel synthesis to replace multiple image series in head CT
Diehn, Felix E. , Nagelschneider, Alex A. , Passe, Theodore J. , Nelson, Brandon , Cardona, Daniel Gomez , Huber, Nathan R. , Missert, Andrew D, Yu, Lifeng , Johnson, Matthew P. , Holmes, David R. , Lee, Yong S. , Thorne, Jamison E. , Diehn, Felix E , DeLone, David R. , Nelson, Brandon J, Gomez Cardona, Daniel G , Thorne, Jamison E , Fletcher, Joel G , Inoue, Akitoshi , Missert, Andrew D, Yu, Lifeng , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Acta Radiologica | October 17, 2024 | Volume: 65 | Issue: 11 | Pages: 1411-1421

10.1177/02841851241280365 | PMID 39415759 Get It

Background SynthesiZed Improved Resolution and Concurrent nOise reductioN (ZIRCON) is a multi-kernel synthesis method that creates a single series of thin-slice computed tomography (CT) images displaying low noise and high spatial resolution, increasing reader efficiency and minimizing partial volume averaging. Purpose To compare the diagnostic performance of a single set of ZIRCON images to two routine clinical image series using conventional CT head and bone reconstruction kernels for diagnosing intracranial findings and fractures in patients with trauma or suspected acute neurologic deficit. Material and Methods In total, 50 patients underwent clinically indicated head CT in the ER (15 normal, 35 abnormal cases). A non-reader neuroradiologist established the reference standard. Three neuroradiologists reviewed two routine clinical series (head and bone kernels) and a single ZIRCON series, detecting intracranial findings or fractures and rating confidence (0–100). Sensitivity, specificity, and jackknife free-response receiver operating characteristic (JAFROC) figure of merit (FOM) were compared (limit of non-inferiority: −0.10). Results ZIRCON and conventional images demonstrated comparable performance for fractures (sensitivity: 51.5% vs. 54.5%; specificity: 40.2% vs. 34.2%) and intracranial findings (sensitivity: 88.2% vs. 91.4%; specificity: 77.2% vs. 73.7%).The estimated difference of JAFROC FOM demonstrated ZIRCON non-inferiority for acute pathologies overall (0.003 [95% CI=−0.051–0.057]) and fractures (0.048 [95% CI=−0.050–0.145]) but not for intracranial findings alone (−0.024 [95% CI=−0.100–0.052]). Conclusion Thin-slice, low noise, and high spatial resolution images can be created to display intracranial findings and fractures replacing multiple images series in head CT with similar performance. Future studies in more patients and further algorithmic development are warranted.
Outcomes of Radiofrequency Ablation for Autonomously Functioning Thyroid Adenomas—Mayo Clinic Experience
Dhanasekaran, Maheswaran , Schmitz, John J. , Castro, M. Regina , Rajwani, Aadil, Lee, Robert Alan, Hamadi, Dana , Callstrom, Matthew R. , Schmitz, John, Castro, Maria Regina, Stan, Marius N , Morris, John C, Stan, Marius N.

Mayo Clinic

Journal of the Endocrine Society | October 17, 2024 | Volume: 8 | Issue: 12 | Pages: No page available

10.1210/jendso/bvae175 | PMID 39502476 Get It

Abstract Background Autonomously functioning thyroid nodules (AFTNs) constitute 5% to 7% of thyroid nodules and represent the second most common cause of hyperthyroidism following Graves’ disease. Currently, radioactive iodine (RAI) and surgery are the standard treatment options, and both incur a risk of postprocedural hypothyroidism and other surgery and radiation-related complications. Methods This work aimed at assessing the efficacy of radiofrequency ablation (RFA) as an alternative treatment option for resolving hyperthyroidism and the nodule volume rate reduction (VRR) and its associated adverse events. Results A total of 22 patients underwent RFA for a solitary AFTN. Seventy-two percent (n = 16) had subclinical hyperthyroidism, 9% (n = 2) had overt hyperthyroidism, and 18% (n = 4) were biochemically euthyroid on antithyroid medication. Average pretreatment TSH was 0.41 mIU/L (SD = 0.98) and free T4 1.29 ng/dL (SD = 0.33). Following a single RFA session, hyperthyroidism resolved in 90.9% (n = 20) and average VRR (61.13%) was achieved within 3 to 6 months following the ablation. Except for 1 nodule, none of the nodules grew during the follow-up period (16.5 months). Two patients (9%) developed transient tachycardia requiring short-term beta-blocker therapy, and 2 developed mild hypothyroidism requiring levothyroxine therapy. Two patients developed recurrent hyperthyroidism and elected to undergo lobectomy and repeat RFA respectively. No serious adverse effects were noted in this cohort. Conclusion RAI and/or surgery represent the standard of care for toxic adenomas, but RFA shows excellent efficacy and safety profile. Therefore, at centers with RFA expertise, it should be considered an alternative treatment strategy, avoiding radiation and surgery-related complications.
P14.05.A A PROSPECTIVE, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
Ozair, Ahmad , Sahgal, Arjun , Groot, John Frederick De, Hibert, Matthew , Zhu, James , Achrol, Achal S. , Shah, Bhavya , Patel, Toral , Rincon-Toroella, Jordina, Sporrer, Justin, Hilliard, Justin D. , Bezchlibnyk, Yarema , Rezai, Ali R. , Lipsman, Nir , Woodworth, Graeme F., Ozair, Ahmad , Ahluwalia, Manmeet S. , Burns, Terry C. , McDermott, Michael , Mogilner, Alon Y. , Mishra, Mark V. , Everson, Richard G. , Weinberg, Jeffrey S. , Cifarelli, Christopher P.

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v77-v78

10.1093/neuonc/noae144.256 Get It

Abstract BACKGROUND Liquid biopsy in glioblastoma (GBM) is hindered by a lack of requisite circulating tumor (ct) and cell-free (cf) DNA levels in blood due to the blood-brain barrier (BBB). This limits the identification of blood-based tumor biomarkers along with the development and use of biomarker-driven systemic therapies. Real-time image-guided low intensity focused ultrasound (LIFU) combined with intravenously administered microbubble oscillators, leads to non-invasive disruption of the BBB. This trial aims to evaluate the utility of LIFU for boosting blood ctDNA and cfDNA for enhanced liquid biopsy in GBM patients. MATERIAL AND METHODS LIBERATE is an ongoing, prospective, multi-center, self-controlled, pivotal trial evaluating safety and technical efficacy of LIFU-based BBB disruption for increasing blood ctDNA and cfDNA levels in adults, aged 18-80 years with GBM. Patients with suspected GBM planned for tumor biopsy or resection at ten centers in the US are being enrolled. Patients with multifocal tumors or tumors arising from deep midline, thalamus, cerebellum, or brainstem are excluded. Patients are administered IV microbubbles for enhanced sonication effects, after which MR-guided BBB disruption using a 220 kHz LIFU device is performed with real-time acoustic feedback control for effective microbubble activation. Before and after procedure, phlebotomy and MRI brain are performed to evaluate outcomes. Primary study endpoint is defined, per subject, as ratio between their cfDNA level in blood 1-hour post-LIFU procedure compared to cfDNA level in blood pre-procedure. Primary study hypothesis is that BBB disruption with LIFU leads to a ≥2-fold rise in blood cfDNA. The secondary hypothesis is that there exists ≥75% agreement between biomarker pattern in blood cfDNA sample obtained 1-hour post-LIFU and the biomarker pattern in tumor tissue obtained later. The trial has been powered to evaluate both primary and secondary hypotheses. Based on an assumed true agreement rate of 91% and a one-sided alpha of 0.025, an exact test for binomial proportions provides a sample of N = 50 with 84% power for the secondary hypothesis. Exploratory endpoints include (1) sensitivity of detection of known specific somatic mutations in ctDNA from blood samples collected before and after LIFU, (2) estimation of ctDNA levels post-LIFU in samples collected at 30 minutes, 1 hour, 2 hour, and 3 hour to determine the time of greatest yield, (3) correlation of MRI parameters related to grading of BBB disruption and ctDNA-based biomarkers from post-LIFU blood samples. RESULTS Patient enrollment commenced in 2022, and 22 patients have been recruited by 05/2024. CONCLUSION Findings from this trial will be critical to liquid biopsy in GBM (Clinical trial information: NCT05383872).
The canine homolog of human receptive speech area responds selectively to social reinforcement
Miller, Kai J. , Lampert, F. , Kim, Inyong , Ince, Nuri F. , Hermes, Dora, Lampert, Frederik, Mívalt, Filip , Kim, Jiwon W. , Křemen, Václav , Baker, Matthew , Boom, Max van den , Hermes, Dora , Coenen, Volker Arnd , Schalk, Gerwin , Brunner, Peter , Worrell, Gregory A.

Mayo Clinic

No container title available | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5183241/v1 Get It

Abstract Studying mammalian brain function aids our understanding of human brain evolution. We implanted a beagle with a prototype human neuromodulation platform that measures activity from the brain surface. One year later, a set of simple sensory tasks was performed, finding visual and somatosensory representation in the canine homologs of the expected areas in humans. Surprisingly, the canine anterior ectosylvian gyrus, which is anatomically homologous to human receptive speech areas, was selectively active during independent social reinforcement tasks. This suggests that human speech understanding may have evolved from more general mammalian brain structures that are specialized for social reinforcement.